Skip to main content
Top
Published in: Thrombosis Journal 1/2024

Open Access 01-12-2024 | Research

Regulation of tissue factor activity by interaction with the first PDZ domain of MAGI1

Authors: Mohammad A. Mohammad, Sophie Featherby, Camille Ettelaie

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

Background

Tissue factor (TF) activity is stringently regulated through processes termed encryption. Post-translational modification of TF and its interactions with various protein and lipid moieties allows for a multi-step de-encryption of TF and procoagulant activation. Membrane-associated guanylate kinase-with inverted configuration (MAGI) proteins are known to regulate the localisation and activity of a number of proteins including cell-surface receptors.

Methods

The interaction of TF with MAGI1 protein was examined as a means of regulating TF activity. MDA-MB-231 cell line was used which express TF and MAGI1, and respond well to protease activated receptor (PAR)2 activation. Proximity ligation assay (PLA), co-immunoprecipitation and pull-down experiments were used to examine the interaction of TF with MAGI1-3 proteins and to investigate the influence of PAR2 activation. Furthermore, by cloning and expressing the PDZ domains from MAGI1, the TF-binding domain was identified. The ability of the recombinant PDZ domains to act as competitors for MAGI1, allowing the induction of TF procoagulant and signalling activity was then examined.

Results

PLA and fluorescence microscopic analysis indicated that TF predominantly associates with MAGI1 and less with MAGI2 and MAGI3 proteins. The interaction of TF with MAGI1 was also demonstrated by both co-immunoprecipitation of TF with MAGI1, and co-immunoprecipitation of MAGI1 with TF. Moreover, activation of PAR2 resulted in reduction in the association of these two proteins. Pull-down assays using TF-cytoplasmic domain peptides indicated that the phosphorylation of Ser253 within TF prevents its association with MAGI1. Additionally, the five HA-tagged PDZ domains of MAGI1 were overexpressed separately, and the putative TF-binding domain was identified as PDZ1 domain. Expression of this PDZ domain in cells significantly augmented the TF activity measured both as thrombin-generation and also TF-mediated proliferative signalling.

Conclusions

Our data indicate a stabilising interaction between TF and the PDZ-1 domain of MAGI1 and demonstrate that the activation of PAR2 disrupts this interaction. The release of TF from MAGI1 appears to be an initial step in TF de-encryption, associated with increased TF-mediated procoagulant and signalling activities. This mechanism is also likely to lead to further interactions and modifications leading to further enhancement of procoagulant activity, or the release of TF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kirchhofer D, Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol. 1996;7(4):386–91.PubMedCrossRef Kirchhofer D, Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol. 1996;7(4):386–91.PubMedCrossRef
2.
go back to reference Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Thromb Haemost. 1997;78(1):401–5.PubMedCrossRef Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Thromb Haemost. 1997;78(1):401–5.PubMedCrossRef
4.
go back to reference Butenas S, Amblo-Krudysz J, Mann KG. Posttranslational modifications of tissue factor. Front Biosci (Elite Ed). 2012;4:381–91.PubMedCrossRef Butenas S, Amblo-Krudysz J, Mann KG. Posttranslational modifications of tissue factor. Front Biosci (Elite Ed). 2012;4:381–91.PubMedCrossRef
5.
go back to reference Egorina EM, Sovershaev MA, Osterud B. Regulation of tissue factor procoagulant activity by post-translational modifications. Thromb Res. 2008;122(6):831–7.PubMedCrossRef Egorina EM, Sovershaev MA, Osterud B. Regulation of tissue factor procoagulant activity by post-translational modifications. Thromb Res. 2008;122(6):831–7.PubMedCrossRef
6.
go back to reference Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999;10(4):201–10.PubMedCrossRef Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999;10(4):201–10.PubMedCrossRef
7.
go back to reference Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost. 2013;11(Suppl 1):277–84.PubMedCrossRef Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost. 2013;11(Suppl 1):277–84.PubMedCrossRef
8.
go back to reference Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood. 1992;80(4):966–74.PubMedCrossRef Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood. 1992;80(4):966–74.PubMedCrossRef
9.
go back to reference Xu Z, Peng AW, Oshima K, Heller S. MAGI-1, a candidate stereociliary scaffolding protein, associates with the tip-link component cadherin 23. J Neurosci. 2008;28(44):11269–76.PubMedPubMedCentralCrossRef Xu Z, Peng AW, Oshima K, Heller S. MAGI-1, a candidate stereociliary scaffolding protein, associates with the tip-link component cadherin 23. J Neurosci. 2008;28(44):11269–76.PubMedPubMedCentralCrossRef
10.
go back to reference Subauste MC, Nalbant P, Adamson ED, Hahn KM. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J Biol Chem. 2005;280(7):5676–81.PubMedCrossRef Subauste MC, Nalbant P, Adamson ED, Hahn KM. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J Biol Chem. 2005;280(7):5676–81.PubMedCrossRef
11.
go back to reference Xu J, Paquet M, Lau AG, Wood JD, Ross CA, Hall RA. beta 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD-95. J Biol Chem. 2001;276(44):41310–7.PubMedCrossRef Xu J, Paquet M, Lau AG, Wood JD, Ross CA, Hall RA. beta 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD-95. J Biol Chem. 2001;276(44):41310–7.PubMedCrossRef
12.
go back to reference Tanemoto M, Toyohara T, Abe T, Ito S. MAGI-1a functions as a scaffolding protein for the distal renal tubular basolateral K+ channels. J Biol Chem. 2008;283(18):12241–7.PubMedCrossRef Tanemoto M, Toyohara T, Abe T, Ito S. MAGI-1a functions as a scaffolding protein for the distal renal tubular basolateral K+ channels. J Biol Chem. 2008;283(18):12241–7.PubMedCrossRef
13.
go back to reference Ide N, Hata Y, Nishioka H, Hirao K, Yao I, Deguchi M, Mizoguchi A, Nishimori H, Tokino T, Nakamura Y, Takai Y. Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells. Oncogene. 1999;18(54):7810–5.PubMedCrossRef Ide N, Hata Y, Nishioka H, Hirao K, Yao I, Deguchi M, Mizoguchi A, Nishimori H, Tokino T, Nakamura Y, Takai Y. Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells. Oncogene. 1999;18(54):7810–5.PubMedCrossRef
14.
go back to reference Feng X, Jia S, Martin TA, Jiang WG. Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein. Anticancer Res. 2014;34(7):3251–6.PubMed Feng X, Jia S, Martin TA, Jiang WG. Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein. Anticancer Res. 2014;34(7):3251–6.PubMed
15.
go back to reference Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014;36:157–65.PubMedCrossRef Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014;36:157–65.PubMedCrossRef
16.
go back to reference Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A. 2000;97(8):4233–8.PubMedPubMedCentralCrossRef Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A. 2000;97(8):4233–8.PubMedPubMedCentralCrossRef
17.
go back to reference Li X, Li Z, Li N, Qi J, Fan K, Yin P, Zhao C, Liu Y, Yao W, Cai X, Wang L, Zha X. MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability. Int J Mol Med. 2013;32(2):439–47.PubMedCrossRef Li X, Li Z, Li N, Qi J, Fan K, Yin P, Zhao C, Liu Y, Yao W, Cai X, Wang L, Zha X. MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability. Int J Mol Med. 2013;32(2):439–47.PubMedCrossRef
18.
go back to reference Valiente M, Andrés-Pons A, Gomar B, Torres J, Gil A, Tapparel C, Antonarakis SE, Pulido R. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem. 2005;280(32):28936–43.PubMedCrossRef Valiente M, Andrés-Pons A, Gomar B, Torres J, Gil A, Tapparel C, Antonarakis SE, Pulido R. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem. 2005;280(32):28936–43.PubMedCrossRef
19.
go back to reference Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001;61(13):4985–9.PubMed Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001;61(13):4985–9.PubMed
20.
go back to reference Ettelaie C, Collier MEW, Featherby S, Benelhaj NE, Greenman J, Maraveyas A. Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J. 2016;14:2.PubMedPubMedCentralCrossRef Ettelaie C, Collier MEW, Featherby S, Benelhaj NE, Greenman J, Maraveyas A. Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J. 2016;14:2.PubMedPubMedCentralCrossRef
21.
go back to reference Mohammad MA, Greenman J, Maraveyas A, Ettelaie C. Activation of PAR2 by tissue factor induces the release of the PTEN from MAGI proteins and regulates PTEN and Akt activities. Sci Rep. 2020;10(1):20908.PubMedPubMedCentralCrossRef Mohammad MA, Greenman J, Maraveyas A, Ettelaie C. Activation of PAR2 by tissue factor induces the release of the PTEN from MAGI proteins and regulates PTEN and Akt activities. Sci Rep. 2020;10(1):20908.PubMedPubMedCentralCrossRef
22.
go back to reference ElKeeb AM, Collier ME, Maraveyas A, Ettelaie C. Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thromb Haemost. 2015;114(2):364–78.PubMed ElKeeb AM, Collier ME, Maraveyas A, Ettelaie C. Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thromb Haemost. 2015;114(2):364–78.PubMed
24.
go back to reference Collier MEW, Ettelaie C, Goult BT, Maraveyas A, Goodall AH. Investigation of the Filamin A-Dependent Mechanisms of Tissue Factor Incorporation into Microvesicles. Thromb Haemost. 2017;117(11):2034–44.PubMedCrossRef Collier MEW, Ettelaie C, Goult BT, Maraveyas A, Goodall AH. Investigation of the Filamin A-Dependent Mechanisms of Tissue Factor Incorporation into Microvesicles. Thromb Haemost. 2017;117(11):2034–44.PubMedCrossRef
25.
go back to reference Ettelaie C, Collier MEW, Featherby S, Greenman J, Maraveyas A. Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles. Biochim Biophys Acta. 2018;1865(1):12–24.CrossRef Ettelaie C, Collier MEW, Featherby S, Greenman J, Maraveyas A. Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles. Biochim Biophys Acta. 2018;1865(1):12–24.CrossRef
26.
go back to reference Collier ME, Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem. 2011;286(14):11977–84.PubMedPubMedCentralCrossRef Collier ME, Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem. 2011;286(14):11977–84.PubMedPubMedCentralCrossRef
27.
go back to reference Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood. 1987;70(2):490–3.PubMedCrossRef Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood. 1987;70(2):490–3.PubMedCrossRef
28.
go back to reference Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. Quantitative real-time reverse transcription-pcr assay for cyclin d1 expression: Utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47(2):195–201.PubMedCrossRef Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. Quantitative real-time reverse transcription-pcr assay for cyclin d1 expression: Utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47(2):195–201.PubMedCrossRef
29.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedCrossRef
30.
go back to reference Ettelaie C, Featherby S, Rondon AMR, Greenman J, Versteeg HH, Maraveyas A. De-Palmitoylation of Tissue Factor Regulates Its Activity, Phosphorylation and Cellular Functions. Cancers (Basel). 2021;13(15):3837.PubMedCrossRef Ettelaie C, Featherby S, Rondon AMR, Greenman J, Versteeg HH, Maraveyas A. De-Palmitoylation of Tissue Factor Regulates Its Activity, Phosphorylation and Cellular Functions. Cancers (Basel). 2021;13(15):3837.PubMedCrossRef
31.
go back to reference Dorfleutner A, Ruf W. Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood. 2003;102(12):3998–4005.PubMedCrossRef Dorfleutner A, Ruf W. Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood. 2003;102(12):3998–4005.PubMedCrossRef
32.
go back to reference Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004;279(22):23038–44.PubMedCrossRef Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004;279(22):23038–44.PubMedCrossRef
33.
go back to reference Ettelaie C, Elkeeb AM, Maraveyas A, Collier ME. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochim Biophys Acta. 2013;1833(3):613–21.PubMedCrossRef Ettelaie C, Elkeeb AM, Maraveyas A, Collier ME. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochim Biophys Acta. 2013;1833(3):613–21.PubMedCrossRef
34.
go back to reference Collier ME, Maraveyas A, Ettelaie C. Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Thromb Haemost. 2014;111(4):647–55.PubMedCrossRef Collier ME, Maraveyas A, Ettelaie C. Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Thromb Haemost. 2014;111(4):647–55.PubMedCrossRef
35.
go back to reference Koizume S, Ito S, Yoshioka Y, Kanayama T, Nakamura Y, Yoshihara M, Yamada R, Ochiya T, Ruf W, Miyagi E, Hirahara F, Miyagi Y. High-level secretion of tissue factor-rich extracellular vesicles from ovarian cancer cells mediated by filamin-A and protease-activated receptors. Thromb Haemost. 2016;115(2):299–310.PubMedCrossRef Koizume S, Ito S, Yoshioka Y, Kanayama T, Nakamura Y, Yoshihara M, Yamada R, Ochiya T, Ruf W, Miyagi E, Hirahara F, Miyagi Y. High-level secretion of tissue factor-rich extracellular vesicles from ovarian cancer cells mediated by filamin-A and protease-activated receptors. Thromb Haemost. 2016;115(2):299–310.PubMedCrossRef
36.
go back to reference Yu Y, Böing AN, Hau CM, Hajji N, Ruf W, Sturk A, Nieuwland R. Tissue factor coagulant activity is regulated by the plasma membrane microenvironment. Thromb Haemost. 2018;118(6):990–1000.PubMedCrossRef Yu Y, Böing AN, Hau CM, Hajji N, Ruf W, Sturk A, Nieuwland R. Tissue factor coagulant activity is regulated by the plasma membrane microenvironment. Thromb Haemost. 2018;118(6):990–1000.PubMedCrossRef
37.
go back to reference Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky LA. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem. 2000;275(28):21477–85.PubMedCrossRef Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky LA. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem. 2000;275(28):21477–85.PubMedCrossRef
38.
go back to reference Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276(52):48627–30.PubMedCrossRef Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276(52):48627–30.PubMedCrossRef
39.
go back to reference Laura RP, Ross S, Koeppen H, Lasky LA. MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp Cell Res. 2002;275(2):155–70.PubMedCrossRef Laura RP, Ross S, Koeppen H, Lasky LA. MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp Cell Res. 2002;275(2):155–70.PubMedCrossRef
40.
go back to reference Kurakula K, Koenis DS, Herzik MA Jr, Liu Y, Craft JW Jr, van Loenen PB, Vos M, Tran MK, Versteeg HH, Goumans MTH, Ruf W, de Vries CJM, Şen M. Structural and cellular mechanisms of peptidyl-prolyl isomerase Pin1-mediated enhancement of Tissue Factor gene expression, protein half-life, and pro-coagulant activity. Haematologica. 2018;103(6):1073–82.PubMedPubMedCentralCrossRef Kurakula K, Koenis DS, Herzik MA Jr, Liu Y, Craft JW Jr, van Loenen PB, Vos M, Tran MK, Versteeg HH, Goumans MTH, Ruf W, de Vries CJM, Şen M. Structural and cellular mechanisms of peptidyl-prolyl isomerase Pin1-mediated enhancement of Tissue Factor gene expression, protein half-life, and pro-coagulant activity. Haematologica. 2018;103(6):1073–82.PubMedPubMedCentralCrossRef
41.
go back to reference Ivanova S, Repnik U, Banks L, Turk V, Turk B. Cellular localization of MAGI-1 caspase cleavage products and their role in apoptosis. Biol Chem. 2007;388(11):1195–8.PubMedCrossRef Ivanova S, Repnik U, Banks L, Turk V, Turk B. Cellular localization of MAGI-1 caspase cleavage products and their role in apoptosis. Biol Chem. 2007;388(11):1195–8.PubMedCrossRef
42.
go back to reference Rothmeier AS, Marchese P, Petrich BG, Furlan-Freguia C, Ginsberg MH, Ruggeri ZM, Ruf W. Caspase-1-mediated pathway promotes generation of thromboinflammatory microparticles. J Clin Invest. 2015;125(4):1471–84.PubMedPubMedCentralCrossRef Rothmeier AS, Marchese P, Petrich BG, Furlan-Freguia C, Ginsberg MH, Ruggeri ZM, Ruf W. Caspase-1-mediated pathway promotes generation of thromboinflammatory microparticles. J Clin Invest. 2015;125(4):1471–84.PubMedPubMedCentralCrossRef
Metadata
Title
Regulation of tissue factor activity by interaction with the first PDZ domain of MAGI1
Authors
Mohammad A. Mohammad
Sophie Featherby
Camille Ettelaie
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00580-6

Other articles of this Issue 1/2024

Thrombosis Journal 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine